Pipeline

NKGen Biotech is conducting numerous clinical trials to discover how natural killer (NK) cells can help patients with neurodegenerative disease and cancer.

Troculeucel (SNK01), NKGen Biotech’s autologous NK cell therapy candidate, has active and planned clinical trials in several therapeutic areas, including oncology and neurodegeneration. This approach allows us to evaluate the potential benefits of adoptive cellular immunotherapy for multiple biologically relevant disease areas. Phase 2 clinical trial is in progress for troculeucel (autologous NK cell therapy).